GlobeStar Therapeutics EBIT

GlobeStar Therapeutics posts a EBIT of $-800K as of June 2024. That compares with $-1.9M in the prior-year period — up 57.5% year over year. That is below the Industrials sector average of $160B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, GlobeStar Therapeutics's EBIT was $-1.9M. The latest reading is $-800K — a 57.5% year-over-year increase (period ending June 2024). Use the history and growth charts on this page for a longer lookback.

For Industrials stocks, a EBIT near $160B is typical. GlobeStar Therapeutics's $-800K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of GlobeStar Therapeutics's financial statement story. At $-800K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GSTC's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $160B), and (3) consistency with growth and profitability. This page covers the first two; GlobeStar Therapeutics's other metric pages and overview cover the third.